Peter E. Boyd - 07 Mar 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
11 Mar 2025, 17:47:19 UTC
Prior SEC filing
12 Mar 2024
Next SEC filing
08 Sep 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Peter E. Boyd filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 11 Mar 2025.

Key facts

  • This page summarizes Peter E. Boyd's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 11 Mar 2025, 17:47.

Change

  • Previous filing in this sequence was filed on 12 Mar 2024.
  • Current net transaction value: -$37,908.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Award

Transaction value
$0
Shares
+80,000
Change %
+34%
Price
$0.000000
Shares after
317,628
Date
07 Mar 2025
Ownership
Direct
Footnotes
F1
AQST transaction

Common Stock

Tax liability

Transaction value
$17,554
Shares
-6,624
Change %
-2.1%
Price
$2.65
Shares after
311,004
Date
07 Mar 2025
Ownership
Direct
Footnotes
F2
AQST transaction

Common Stock

Tax liability

Transaction value
$20,355
Shares
-7,681
Change %
-2.5%
Price
$2.65
Shares after
303,323
Date
09 Mar 2025
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
$0
Shares
+40,000
Change %
Price
$0.000000
Shares after
40,000
Date
07 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,000
Exercise price
$2.65
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Footnote F2

Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Footnote F3

The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC remarks

SVP, Information Technology, Human Resources and Communications

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .